.Attributes Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients along with HER2+ advanced breast cancer cells as well as active or steady mind metastases revealed consistent intracranial task and wide spread efficiency of T-DXd.